Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04987333
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 1
Start date August 9, 2021
Completion date October 3, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05656378 - A Repository to Study Host-Microbiome Interactions in Health and Disease
Completed NCT00734240 - Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers Phase 1
Completed NCT03044873 - Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin Phase 1
Terminated NCT01364389 - A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Phase 2
Recruiting NCT06065592 - Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms Phase 1
Recruiting NCT05662033 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy Subjects and to Assess the Relative Oral Bioavailability Between Two Formulations. The Study Will Also Assess the Food Effect on the PK of AZD6793 Compared to Fasting State Phase 1
Active, not recruiting NCT01981785 - Investigation of Immune Disorders and Deficiencies N/A